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ThediagnosisofprobableAlzheimer’sdisease(AD)canbeestablishedpremortembasedonclinicalcriterialikeneuropsychological
tests. Post mortem, speciﬁc neuropathological changes like amyloid plaques deﬁne AD. However, the standard criteria based
on medical history and mental status examinations do not take into account the long preclinical features of the disease, and
a biomarker for improved diagnosis of AD is urgently needed. In a large number of studies, amyloid-β (Aβ) monomer con-
centrations in CSF of AD patients are consistently and signiﬁcantly reduced when compared to healthy controls. Therefore,
monomeric Aβ in CSF was suggested to be a helpful biomarker for the diagnosis of preclinical AD. However, not the monomeric
form, but Aβ oligomers have been shown to be the toxic species in AD pathology, and their quantiﬁcation and characterization
could facilitate AD diagnosis and therapy monitoring. Here, we review the current status of assay development to reliably and
routinely detect Aβ oligomers and high-molecular-weight particles in CSF.
1.Introduction
Alzheimer’s disease (AD) is a detrimental neurodegenerative
disorder and the most common cause of dementia. AD
results in memory loss and behavioral problems, leading to
disastrous impact on the patient’s life and on that of the pa-
tient’s relatives. It was estimated that approximately 27 mil-
lion people are aﬀected worldwide. As aging is one of the
main risk factors for AD and people grow steadily older, the
number of aﬄicted people is expected to quadruble by 2050
[1].
The amyloid-β (Aβ) peptide has been identiﬁed to play a
major role in the pathology of AD. The 4kDa peptide, con-
sisting of 39 to 42 amino acid residues, is derived from
the proteolysis of the amyloid precursor protein (APP) by
two diﬀerent proteases, β-a n dγ-secretase [2–4]. Aβ is the
main component of amyloid plaques associated with AD
[5]. The amyloid cascade hypothesis states that Aβ aggre-
gation followed by plaque formation is a central event in AD
[6]. Today, it is well known that diﬀusable and soluble Aβ
oligomeric species are the main toxic species in AD. Aβ ol-
igomers have been shown to impair long-term potentiation
(LTP), decrease the density of dendritic spines in hippocam-
pal brain slices in vitro and impair memory in vivo.F i b r i l l a r
Aβ deposited in plaques was shown to exhibit comparably
low toxic eﬀects, and the plaque load in the brain does not
correlate well with the symptomatic disease progress [7–10].
Today, the diagnosis of deﬁnite AD requires clinical diag-
nosis, based on the observation of clinical symptoms, and
postmortem detection of amyloid plaques and neuroﬁbril-
lary tangles, the latter composed of aggregated tau protein,
in the brain tissue of the deceased patient. The diagnosis
“probable AD” can be established with 50% to 90% certainty
dependent on clinical criteria, neuropsychological testing,
and laboratory tests [11–13]. The ﬁrst molecular events lead-
ing to AD, like Aβ oligomerization and plaque deposition as2 International Journal of Alzheimer’s Disease
well as tau pathology, are supposed to appear 10 to 20 years
before the symptoms become apparent [11–16]. Therefore,
new criteria for diagnostic research have been proposed with
the aim to incorporate supportive biomarker information,
for example, CSF Aβ and tau monomer concentration, glu-
cose and amyloid imaging using positron emission tomog-
raphy (PET), and magnetic resonance spectroscopy (MRS)
for the detection of brain atrophy to allow a more sensitive
and speciﬁc diagnosis of AD in preclinical stages, that is,
when symptoms are not yet apparent [17, 18].
Biomarkers that are directly or indirectly related to the
pathophysiological changes of AD might be auxiliary to
d i a gn o s eA Dd i ﬀerentially in preclinical stages. Early diagno-
sis will aid treatment decisions substantially, as currently the
majority of scientists agree that AD treatment will be most
eﬀective in early stages of the disease [19]. At present, only
symptomatic treatment of AD is available, but several com-
pounds are currently being developed, most of them aiming
at Aβ, for example, secretase inhibitors, immunotherapy
and Aβ aggregation inhibitors [19–21] .M o r et h a n1 0c o m -
pounds are currently in clinical phase III trials, and several
more in phase I or II. Referring to PubMed, hundreds of
compounds are in the preclinical state. Furthermore, bio-
markers will be needed to select and characterize the patients
to be enrolled in clinical studies as well as to monitor the ef-
fects of the drug candidates [22].
A variety of studies have shown that reduced levels of
Aβ1-42monomers,inmostcasesdeterminedbyELISAorre-
lated methods, implicate a high predictive value for the iden-
tiﬁcation of prodromal AD in cases of mild cognitive impair-
ment (MCI). CSF concentrations of monomeric Aβ1-42 are
reduced by 30 to 50 percent in AD patients compared to
age-matched, nondemented controls as conﬁrmed in many
independent studies, with both sensitivity and speciﬁcity ex-
ceeding 80 to 90% in most of them. There is evidence sug-
gesting that combined biochemical analysis of tau and phos-
phorylated tau, which both are increased in CSF of AD pa-
tients in comparison to controls, and Aβ measurements in
CSF can improve the diagnostic value as it can even predict
AD with sensitivity and speciﬁcity values of 80 to 90% [23].
A variety of biomarker studies have also been performed in
plasma, but the results are rather inconsistent, and at present
the convenience to detect Aβ1-42 as a biomarker in plasma
has not been proven yet (reviewed in [24, 25]).
However, the monomeric form of Aβ is not the main
responsible isoform for neurotoxicity and neurodegenera-
tion. Aβ oligomers have been shown to play a fundamental
neurotoxic role in AD pathology, and the ability to quantify
and qualify them as well as insoluble high-molecular-weight
(HMW) aggregates could not only enhance AD diagnosis,
but also help to investigate the contribution of Aβ aggregates
to AD pathology. The development of techniques for the
reliable detection of Aβ aggregates, however, is technically
challenging due to the heterogeneous and unstable nature
of such particles, which steadily interconvert into each other,
and their low abundance. Here, we review the current status
of assay development to reliably and routinely detect Aβ oli-
gomers and HMW particles in CSF. We especially focus
on the development of methods with single Aβ aggregate
sensitivity. Methods which were successfully developed but
not yet applied to human body ﬂuids were not included. All
types of methods reviewed here are summarized in Figure 1.
In this review, the term “aggregates” describes all kinds of
non-monomeric Aβ conformers including oligomers, pro-
toﬁbrils and ﬁbrils. Aβ oligomers are deﬁned as nonﬁbrillar,
soluble low-molecular-weight conformers. The term HMW
particles describes unsoluble Aβ conformers. Phrases de-
scribing special Aβ species are used as by the authors of the
reviewed methods.
2. MethodsfortheDetectionofAβAggregatesin
CSF, Resulting inOne SummarizedSignal
Starting in 2005, a variety of articles were published that de-
scribe techniques for the detection of Aβ aggregates in body
ﬂuids. All methods are based on Aβ caption using speciﬁc
antibodies, and they result in the summarized quantity of Aβ
aggregates as readout, either via nanotechnology or ELISA-
basedtools.ThedetectionofAβmonomersisexcludedeither
by oligomer speciﬁc antibodies or application of the same
Aβ-binding antibody twice in the system, for example, as
capture as well as detection antibody. Because the binding
epitope in monomers will already be occupied by the capture
antibody, dimers are supposed to be the smallest detectable
unit. The latter methods will also detect HMW Aβ particles
if the samples were not centrifuged before testing.
In 2005, two articles reporting on extremely sensitive
nanotechnology-basedassaysforthedetectionofAβ-derived
diﬀusible ligands (ADDLs) were published. Haes et al. com-
bined ADDL-speciﬁc antibodies with localized surface plas-
mon resonance (LSPR) spectroscopy and investigated the
CSF of one AD patient and one control. Georganopoulou
et al. applied-ADDL speciﬁc antibodies to develop an ultra-
sensitive barcode assay for speciﬁc detection of ADDLs in
CSF. CSF samples of 15 AD patients and 15 controls were
investigated. In both preliminary studies, the AD patient
samples were shown to exhibit higher ADDL concentrations
compared to the controls [26, 27]. After initial publications,
no follow-up articles were published of both ADDL-speciﬁc
assays. That might be due to technical diﬃculties of the tech-
nologies as the reported protocols contained several critical
steps in sample preparation and measurement procedures,
and suitability for application in high throughput or multi-
center studies might be limited.
In 2010, Fukomoto et al. reported on a novel ELISA
method for the speciﬁc detection of high-molecular-weight
(HMW) Aβ oligomers. In the protocol, the same N-terminal
binding Aβ antibody BAN50 was used for capturing the
o l i g o m e r sa sw e l la st od e t e c tt h e m .I nC S Fs a m p l e so f1 8A D
and 7 MCI cases, signiﬁcantly higher signals for Aβ HMW
oligomers were detected as in the 25 nondemented con-
trols. Additionally, an inverse correlation of Aβ oligomer
readout and MMSE scores could be described. The size of
the detected oligomers was determined to be 40 to 200kDa,
mainly fractionating in size exclusion chromatography ex-
perimentsat45to90kDa,representingmainly10to20mers.
Monomers and lower-molecular-weight oligomer species
were not detected [28]. Therefore, the authors provide aInternational Journal of Alzheimer’s Disease 3
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Figure 1: Summary of method types used for the detection of Aβ oligomers in CSF. Sandwich-ELISA methods provide oligomer speciﬁcity
because the same antibody is applied as capture and for detection. Alternatively, oligomer-speciﬁc antibodies can be used in the detection
process. In sandwich nanotechnology tools, two speciﬁc antibodies frame Aβ oligomers. The signal of detection is ampliﬁed, for example,
by conjugated gold nanoparticles with hundreds of DNA barcodes attached in biobarcode assays. The DNA-magnet-sandwich complexes
are extracted from the sample using a magnet. Subsequently, the total number of DNA barcodes is determined. In assays based on seeded
polymerization, preexisting mul-timeric Aβ particles in body ﬂuids are spiked by adding labeled Aβ peptides to the sample. Detection
is performed via ﬂuorescence correlation spectroscopy (FCS). Fluorescence resonance energy transfer (FRET) is a mechanism describing
energy transfer between two chromophores in spatial proximity, which is given between two ﬂuorophores attached to the same Aβ oligomer.
FRET signals are detected by ﬂow cytometry. Surface-FIDA is based on a laser focus scanning the surface of a specially prepared glass chip.
Either a ﬂuorescence correlation spectroscopy (FCS) device or a laser scanning microscope (LSM) can be used. Aβ aggregates or oligomers
areconcentratedinatwo-dimensionalsurfacebyimmobilizingthemonaglassslideusingAβcaptureantibodies.Theaggregatesaredetected
by adding at least two ﬂuorescence-labeled anti-Aβ anti-bodies. At least, two laser beams are focused on the surface of the glass chip, and
the ﬂuorescence light which is emitted by the ﬂuorescence antibodies is detected in a confocal way, enabling single aggregate detection. A
quantitative value for speciﬁc colocalized ﬂuorescence pixels is yielded by the summation of all cross-correlated pixels in the colocalization
area above a threshold (cutoﬀ) intensity value. Only double-labeled events are considered for the analysis.
comparatively technically simple method to detect a special
subset of Aβ conformers.
In 2010, Gao et al. developed peptides which bind Aβ
aggregates and used them as bait for Aβ aggregates in CSF
in the “misfolded protein assay” (MPA). After the aggregates
were bound to aggregate-speciﬁc beads, Aβ was denatured
and the concentration thereof was determined in Aβ1-40
and Aβ1-42 monomer-speciﬁc ELISAs. Interestingly, in CSF
samples of 26 AD patients, higher amounts of Aβ1-40 aggre-
gates could be detected than in the samples of 10 age-
matched controls [29]. The nature of the detected aggregates
remains unclear, as the aggregate-speciﬁc beads were de-
scribed to bind higher-order aggregates as well as Aβ oli-
gomers, and Aβ is denatured for concentration determina-
tionusingconventionalELISAforAβ monomers.Thisinfor-
mation, however, could be helpful for characterization of
AD pathology and development of diagnostic approaches.
In general, the application of ELISA or related assay sys-
tems to analyze body ﬂuids for their content of Aβ aggregates
hasseveraladvantages.ELISAstudiesareeasytoperformand
technically simple, rendering them suitable for multicenter
research. In case Aβ species-speciﬁc antibodies are employed
and only one special Aβ conformer is detected, care has to
be taken that the chosen conformer is really relevant for
AD pathology and diagnosis. A variety Aβ oligomeric con-
formers, ranging from dimers to high-molecular-weight
species, have been described in vitro and in vivo, being highly
diverse with regard to structure and shape [7–9, 30–32]. The
identity of the most relevant Aβ conformer is currently an
active and controversial research topic and might be depend-
ent of the stage of the disease.
Up to date, a variety of conformer-speciﬁc Aβ antibodies
were described, being speciﬁc either for Aβ oligomers, pro-
toﬁbrilsorﬁbrils[33–37].Onlysomeofthemwereemployed
in biomarker studies for the detection of ADDLs in CSF [26,
27] or protoﬁbrils in CSF and blood [38, 39]. To my knowl-
edge, the oligomer-speciﬁc monoclonal antibodies A11
(Millipore), which recognizes all types of amyloid oligom-
ers like, for example, prions, but not monomers and ﬁbrils
[36], and another Aβ oligomer-speciﬁc antibody (clone 4D8,4 International Journal of Alzheimer’s Disease
Gentaur Molecular Products) are commercially available but
were not used in any reported biomarker study yet.
Potential cross-reactivity of conformational speciﬁc anti-
bodies for Aβ monomers has to be excluded carefully. Klaver
et al. tested the speciﬁcity and sensitivity of an ELISA pro-
cedure in which the N-terminal binding Aβ antibody 6E10
was used as capture and for detection. It could be shown that
in the described assay, Aβ monomers were detected at least
to a certain extent [40]. Additionally, Sehlin et al. stated that
positive results generated by Aβ oligomer ELISA assays could
be caused by heterophilic antibodies, which are abundant in
CSF and recognize immunoglobulins of other species. Het-
erophilicantibodiesinterferedinsandwichimmunoassaysby
cross-binding capture and detection antibodies and caused
falsepositiveresults[41].AnotherdrawbackofELISAstudies
for the detection of oligomers might be the underestimation
of the number of molecules which was described by Stenh
et al. [42].
One disadvantage of the methods described above is that
one summarized signal for all particles under investigation is
generated. In case conformer-speciﬁc antibodies are applied,
structurally diﬀerent Aβ oligomer species in the sample will
remain undetected. In the next paragraph of this review,
we will focus on methods based on single particle detection
methodologies like ﬂuorescence correlation spectroscopy
and laser scanning microscopy. Methods with single particle
sensitivity allow, per deﬁnition, the most sensitive detection
of Aβ oligomers and HMW particles. In addition, in some
of the methods, characterization of the single particles under
investigation, for example, in respect of size, form, texture,
and composition, is possible. At the end, detailed quantif-
ication and characterization of Aβ aggregates might lead to
a better understanding of the contribution of Aβ oligomers
and HMW particles to AD pathology.
3. Methods for Detection and Characterization
of Single Aβ Aggregates in CSF
To date, only very few methods for the detection of single
Aβ aggregates in body ﬂuids were described in the literature.
One reason might be that technologies to detect at the single
molecule level, like ﬂuorescence correlation spectroscopy
(FCS), laser scanning microscopy (LSM) with sensitive de-
tectors and ﬂow cytometry, are prone to ﬂuorescence back-
ground or other artifacts and can generate false positive sig-
nals.SignalsarisingfromAβ oligomers,whichhaveacompa-
rably small size, have to be clearly distinguished from signals
arisingfrommonomersorfromﬂuorescentbackground,and
data analysis has to be adapted very carefully only to count
the signals from Aβ conformers that contribute to AD path-
ology.
TheﬁrstmethodforthedetectionofsingleAβ aggregates
in CSF was described by Pitschke et al. in 1998. The authors
employed the process of seeded polymerization and detected
Aβ aggregates in the CSF of AD patients using FCS. FCS
means correlation analysis of the ﬂuctuations of the ﬂuores-
cence intensities of particles, which vary versus time due to
Brownian motion in solution. Laser light is focused into a
sample passing a dichroic mirror. When ﬂuorescence-labeled
particles cross the focal volume, they ﬂuoresce and the emit-
ted light reaches a very sensitive photomultiplier tube or
avalanche photodiode detector. Light derived from out-of-
focus areas is suppressed by a small aperture in front of the
detectors. In typical FCS applications, the average number of
ﬂuorescent particles and their average diﬀusion time can be
determined and concentration and size of the particles can
be calculated. The ﬂuorescence of particles to be investigated
can be derived by themselves, by labels, or by addition of
ﬂuorescent ligands like antibodies.
Pitschke and coworkers added labeled Aβ peptide, which
was kept in SDS to avoid self-multimerization, to CSF sam-
ples of 15 AD patients and 19 controls. In contrast to reg-
ular FCS applications described above, the ﬂuorescence in-
tensity signal versus time was analyzed, and the frequency of
high-intensity ﬂuorescence peaks was calculated per minute.
Samples from the controls produced a ﬂuctuating, relatively
low ﬂuorescence intensity signal up to 20 minutes after
addition of labeled Aβ. In the samples of the AD patients,
high-intensity ﬂuorescence bursts were detectable. In the
latter, multimeric Aβ particles acted as seeds for rapid poly-
merization of the labeled Aβ monomers, and additional ex-
periments attested that the major component of the particles
was in deed Aβ. Smaller-intensity peaks detected in the
control samples were derived from spontaneous multimer-
ization of the ﬂuorescent probes, but could be clearly distin-
guished from positive signals. The linearity of the assay was
tested with synthetic Aβ and could be veriﬁed to be be-
tween 20 ng to 1000 ng in 20μLs a m p l ev o l u m e[ 43]. There
is only limited information about the size of the aggre-
gates which were originally present in the CSF before addi-
tion of ﬂuorescence-labeled Aβ monomers. Only the ﬂuores-
cence intensity of each single particle could give hints on
aggregate size. This ﬁrst article was the starting point for the
development of methods for detection of Aβ oligomers or
HMW particles in body ﬂuids.
In 2007, Henkel et al. reﬁned the method described by
Pitschke and colleagues and detected large Aβ1-42-binding
particles (denoted LAPs) in the CSF of human AD patients
and controls using a similar measurement principle as de-
scribedabove.Thedetectionsensitivityoftheself-madecon-
focal assay-system was increased 20-fold in (indirect) com-
parison to the system described by Pitschke et al., employing
amicrochannelﬂow-throughsystemandasamplevelocityof
approximately 0.72mm/s. The analysis revealed that spiking
CSF samples with ﬂuorescent Aβ resulted in binding of
the probe to particles preexisting in CSF, producing peaks
of high ﬂuorescence intensity. Aβ autoaggregates, already
signiﬁcantly reduced by ﬁltering the ﬂuorescence-labeled
Aβ, were excluded from the analysis via deﬁnition of an
intensity cut-oﬀ. Only very bright LAPs, three times as the
threshold used by Pitschke et al., were included. LAPs were
detected in samples of 8AD patients and 6 patients with
mixed-type AD as well as in controls (6 nondemented, 10
other neurodegenerative diseases) with high interindividual
variation, but LAP concentration was not speciﬁc for AD.
Next, the group used confocal microscopy to investigate
the particles which acted as seeds in the samples in more
detail. To detect the particles in the ﬂuorescent images,International Journal of Alzheimer’s Disease 5
Aβ1-42 labeled with Cy3 was added to the samples. Using an
imaging analysis routine, area, shape, brightness, and texture
of the particles were determined and the LAPs were grouped
into four classes. Aβ autoaggregates could be clearly deﬁned
by low brightness, small size, and heterogeneous texture.
LAP-1 aggregates were rarely found in CSF and resembled
particles detected when labeled Aβ was added to synthetic
Aβseeds.LAP-2aggregatesseemedtocontainprotein-bound
Aβ aggregates. Both LAP-3 and LAP-4 were bright parti-
cles, either ellipsoid (LAP-3) or round shaped (LAP-4). They
resembled immune complexes that are observed in autoim-
mune diseases. LAPs-4 were virtually absent in all AD pa-
tients but present in approximately 40% of the control sam-
ples. This coherence was discussed as further evidence for a
circulating IgG-based clearance system for soluble Aβ con-
formers [44]. In other studies, naturally occurring Aβ auto-
antibodies were detected to a higher extent in plasma sam-
ples of controls, in comparison to AD patients [45]. The
method described by Henkel et al. revealed very interesting
information about LAPs. In the images, however, the LAPs
look comparably large (up to 2μM), and the results of the
study may be hardly comparable with biomarker studies in
which smaller Aβ aggregates or oligomers were investigated.
In 2007, Santos et al. established a method for Aβ oli-
gomer detection based on ﬂuorescence resonance energy
transfer (FRET) and detection of FRET events by ﬂow cy-
tometry. To label oligomers in CSF, two ﬂuorescence-labeled
Aβ antibodies were added: 4G8-AlexaFluor 488 and 6E10-
AlexaFluor 594. FRET means that energy is transferred
from an excited donor (4G8-AlexaFluor 488) to an acceptor
molecule (6E10-AlexaFluor 594) under deﬁned spatial con-
ditions,leadingtoﬂuorescenceemissionoftheacceptormol-
ecule. FRET events will only occur if both antibodies are in
close spatial distance, that is, if both are bound to the same
Aβ oligomer. Aβ monomers will not be detected as only one
antibody probe can bind, respectively, and if two monomers
are in close distance, the resulting FRET signal will be of very
low intensity. The application of two speciﬁc Aβ antibodies
in the detection process will ensure high speciﬁcity of the
assay. The sensitivity of the method was investigated using
synthetic ADDL and ﬁbril preparations, determined to be
linear in a range of 10pM to 2.5nM, and referred to the mo-
nomer concentration. The detection limit wasset to be in the
femtomolar range. Estimation of Aβ conformer size is possi-
ble due to analysis of the ﬂuorescence intensities of each sin-
gle particle. 174 human CSF samples of nondemented indi-
viduals,samplevolume200μL,wereinvestigatedintheassay.
A large variation of the oligomer concentration was dem-
onstrated, and a weak correlation between the age of the
individuals and the oligomer concentration was stated. The
assay was shown to be highly reproducible [46], but to date
no data obtained from AD patient samples were published.
Instead, in 2008, Santos et al. published a related method for
the detection of Aβ oligomers in plasma samples. Simultane-
ously, the content of Aβ1-40 and Aβ1-42 could be quantiﬁed
using species-speciﬁc Aβ antibodies for immunoprecipita-
tion. The resulting immunocomplexes were immobilized to
magnetic beads, and ﬂuorescence-labeled antibodies were
added. Subsequently, the samples were investigated by ﬂow
cytometry. The amount of Aβ oligomers allowed diﬀeren-
tiation between 17 plasma samples of AD patients and 16
plasma samples of nondemeted controls with a speciﬁcity of
81.2% and a sensitivity of 70.6% [47].
In 2006, Birkmann et al. developed a method for the
detection of single prion particles, counted by FCS. Prion
aggregatesinbrainsamplesofBSE-andScrapie-infectedani-
mals were isolated by chemical precipitation, labeled by two
diﬀerent speciﬁc and ﬂuorescence-labeled prion antibodies,
and detected in FCS using the two-color mode. As several
probe antibodies bind to one aggregate, high ﬂuorescence
intensity peaks are detected if the aggregates cross the laser
focus. Monomers can be distinguished by an intensity
cut-oﬀ. Coincidental signals of both markers were counted
as speciﬁc events. In 2007, the method was reﬁned and used
for the detection of prion protein aggregates in the CSF of
BSE-infected cattle versus controls. In the new assay version,
denominated Surface-FIDA (ﬂuorescence intensity distribu-
tionanalysis),theprionproteinaggregateswereimmobilized
tothesurfaceofaglasschipusingspeciﬁccaptureantibodies.
Then, two ﬂuorescence-labeled detection antibodies were
applied for detection of the aggregates. A scheme of the
measurement principle can be found in the ﬁgure. At least,
three detection antibodies are used in the assay procedure,
providing high speciﬁcity [48]. Additionally, detection of
monomers can be excluded by the application of the same
antibodyascaptureandasdetectionprobe.In2007,theassay
was adapted to the detection of Aβ oligomers. The linearity
of the assay was evaluated using synthetically prepared ag-
gregated Aβ. The assay was shown to be linear over a wide
range of Aβ aggregate amounts in the picogram range. Syn-
thetic Aβ monomers were not detected. As a ﬁrst trial to
perform Surface-FIDA on real CSF samples, 20μLc ru d eC S F
of three AD patients and two nondemented control patients
were subjected to the assay. The count of Aβ aggregates was
higher in AD patients than in healthy controls. Recently,
the assay could be optimized with regard to its biochemical
steps and adapted to LSM, leading to further improvement
of sensitivity. Additionally, using the image-based method,
every single aggregate can be characterized with regard to its
size and composition [49–51]. The inﬂuence of heterophilic
antibodies, as described by Sehlin et al. [41], was not inves-
tigated yet but should be addressed in ongoing studies.
4. Conclusion
The interest of the Alzheimer’s research community to detect
Aβ oligomers and aggregates in body ﬂuids grew strongly in
recent years. Aβ oligomers have been shown to be the main
toxic species in AD pathology, and the ability to quantify
and qualify them could not only enhance AD diagnosis, but
also help to investigate the contribution of Aβ oligomers
and HMW particles to AD pathology. The development of
techniques for the reliable detection and quantitation of
aggregated Aβ species, however, is technically challenging, as
already described in the introduction.
As today indicated by six preliminary but independent
studies, the concentration of Aβ oligomers was higher in
CSF of AD patients than in healthy controls, and one study6 International Journal of Alzheimer’s Disease
even reported on similar results in plasma samples [26–
29, 43, 47, 49]. These results further strengthen the theory
that Aβ oligomers might be a valuable marker for AD diag-
nosis and therapy monitoring. In contrast, Henkel et al. re-
ported that there was no correlation between Aβ aggregate
countanddiagnosis [44].These incoherentresultscanbe ex-
plained by technological diﬀerences and diﬀerences in sam-
plepreparation.Itwasalreadysuggestedthatstandardopera-
tion procedures for sample preparation might lead to more
consistent results, and several research networks are current-
ly working on standardization of sample collection, preana-
lytical and analytical features for the harmonization of AD
biomarker measurements.
The ﬁnding that the concentration of Aβ oligomers is
higher in CSF of AD patients than in healthy controls some-
how seems to contradict ELISA studies suggesting that the
total or monomer Aβ amount decreases with disease pro-
gression. Englund et al., however, found evidence that the
lowering of Aβ42might wellbe causedbyits oligomerization
[52]. Thus, the reported decrease of monomeric Aβ,w h i c h
in fact might just be a decrease of accessible monomeric
Aβ, might well be in good accordance with the observed in-
crease of aggregated Aβ with disease progression. To obtain
reliable information in the future hundreds of samples will
have to be investigated employing diﬀerent assay systems.
Still, a lot of work is needed to elucidate the nature of the
Aβ oligomers relevant to the disease as well as to improve the
technical robustness of the applied quantiﬁcation methods.
Some of the assays reviewed here are complex and their ro-
bustnesswillhavetobeproveninfuture.Aftertheirtechnical
optimization, the most robust and reliable assays could
easily be adapted to other protein aggregates involved in the
pathology of neurodegenerative diseases.
Although lumbar puncture is moderately invasive and
has low incidence of complications [53], biomarkers detect-
able in blood plasma would be of great value for wider diag-
nostic use and for therapy monitoring. It would be very use-
ful to adapt the most robust and sensitive methodology de-
veloped based on CSF to plasma and serum samples. Meas-
urements in plasma, however, are technically much more
challenging. Aβ is well known to bind to plasma proteins
likealbuminandlipoproteins,leadingtomaskingofepitopes
[54]. In 2009, Xia et al. reported on an Aβ oligomer speciﬁc
ELISA. In this study, plasma levels of Aβ42 and oligomeric
Aβ species were strongly correlated across the subjects [55].
In summary, several sensitive assays for the detection and
characterization of Aβ oligomers in CSF are currently devel-
oped. Preliminary results indicate that Aβ oligomers and
HMW particles might be valuable biomarkers for AD, and
biomarker studies on aggregated Aβ species might enlight-
en the role of Aβ aggregates in progression of Alzheimer’s
disease.
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